Hemab Therapeutics Holdings, Inc. Common Stock (COAG) — Cash Flow-to-Debt Ratio
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has a Cash Flow-to-Debt Ratio of -0.17x as of December 2025, meaning its operating cash flow of $-61.48 Million could theoretically repay 0% of its total liabilities ($371.42 Million) in one year. For the full cash flow conversion analysis, see Hemab Therapeutics Holdings, Inc. Common (COAG) cash flow conversion.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hemab Therapeutics Holdings, Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Hemab Therapeutics Holdings, Inc. Common Stock across 2 annual periods. See financial agility of Hemab Therapeutics Holdings, Inc. Common to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow-to-Debt Ratio for Hemab Therapeutics Holdings, Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Hemab Therapeutics Holdings, Inc. Common Stock. See Hemab Therapeutics Holdings, Inc. Common current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.17x | $-61.48 Million | $371.42 Million | ▲ +23.2% |
| 2024 | -0.22x | $-45.59 Million | $211.55 Million | — |